Value-based care (VBC) is already an important part of Medicare. But the next 10 years of VBC will be shaped by the private sector. We detail the position of each major stakeholder: who's most motivated to act, how they can shape future reimbursement models, and what's standing in their way.

When it comes to the future of value-based care (VBC), it’s easy to get caught up in the minutiae of individual contracts or to think of many reasons why large-scale VBC is unlikely to come to fruition, at least in the near term. We’ve talked extensively about the immediate barriers to risk before. But for our current research, we decided to take a different approach.

In our recent analysis of a national commercial data set of professional claims, chemotherapy was the fifth highest-cost sub-service line—and that doesn’t even take drug costs into account. Many of the experts we interviewed were surprised how high chemotherapy was on the commercial list.